Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells

Journal of Immunotherapy

Volumn 34, Issue 8, 2011, Pages 597-605

  Torisu Itakura, Hitoe ^a   Schoellhammer, Hans F ^a   Sim, Myung Shin ^a   Irie, Reiko F ^a   Hausmann, Susanne ^a,b   Raum, Tobias ^b   Baeuerle, Patrick A ^b   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b MICROMET AG   (Germany)

Author keywords

BiTE antibody; MCSP; melanoma; PBMC; T cell

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC T CELL ENGAGING ANTIBODY; CD3 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; MELANOMA ANTIGEN; MELANOMA ASSOCIATED CHONDROITIN SULFATE PROTEOGLYCAN; OKT 3; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES;

EID: 80052971289     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182307fd8     Document Type: Article

References (27)

1. Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11:22-30.
2. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941-4944.
3. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974-977.
4. Brischwein K, Parr L, Pflanz S, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother. 2007;30: 798-807. (Pubitemid 350295358)
5. Haas C, Krinner E, Brischwein K, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology. 2009;214:441-453.
6. Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115:98-104. (Pubitemid 40559673)
7. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317:1255-1260.
8. Trerotola M, Guerra E, Alberti S. Letter to the editor: efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309-1.
9. Biochim Biophys Acta 2010; 1805:119-120; author reply 121-112.
10. Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43: 1129-1143. (Pubitemid 43063166)
11. Schmidt P, Kopecky C, Hombach A, et al. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA. 2011;108: 2474-2479.
12. Natali PG, Bigotti A, Cavaliere R, et al. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst. 1984;73:13-24. (Pubitemid 14090824)
13. Kageshita T, Nakamura T, Yamada M, et al. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res. 1991;51:1726-1732.
14. Campoli MR, Chang CC, Kageshita T, et al. Human high molecular weight-melanoma-associated antigen (HMWMAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004;24:267-296. (Pubitemid 40052428)
15. Bluemel C, Hausmann S, Fluhr P, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother. 2010;59:1197-1209.
16. Karram K, Chatterjee N, Trotter J. NG2-expressing cells in the nervous system: role of the proteoglycan in migration and glialneuron interaction. J Anat. 2005;207:735-744. (Pubitemid 43019733)
17. Burns WR, Zhao Y, Frankel TL, et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 2010;70:3027-3033.
18. Lutterbuese R, Raum T, Kischel R, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother. 2009;32:341-352.
19. Osada T, Hsu D, Hammond S, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer. 2010; 102:124-133.
20. Torisu-Itakura H, Baeuerle PA, Morton DL. T cell-engaging MCSP-specific BiTE antibody showed anti-tumor activity of at very low effector to target ratios. Proc Jpn Dermatol Assoc. 2009. 108th:Abs 10042 [in Japanese].
21. Torisu-Itakura H, Schoellhammer HF, Huynh Y, et al. Antitumor activity of a T cell-engaging MCSP-specific BiTE antibody at very low effector to target ratios: a new approach to treat metastatic melanoma. Proc Am Assoc Cancer Res. 2009;50:786.
22. Schoellhammer HF, Torisu-Itakura H, Sim M, et al. Singlechain bispecific antibody specific for CD3 and melanomaassociated chondroitin sulfate proteoglycan: in vitro and in vivo antimelanoma activity. Proc Am Assoc Cancer Res. 2010;51:1365.
23. McMichael AJ, Beverly P, Gilks W. Leucocyte Typing III: White Cell Differentiation Antigens. New York: Oxford University Press; 1987.
24. Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens. 2009;74:277-289.
25. Uckert W, Schumacher TN. TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol Immunother. 2009;58:809-822.
26. Gattinoni L, Powell DJ Jr., Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
27. Kiss J, Timar J, Somlai B, et al. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma. Pathol Oncol Res. 2007;13:21-31. (Pubitemid 46883543)